摘要
目的探讨局部晚期非小细胞肺癌患者采用支气管动脉灌注重组人p53腺病毒联合同期放化疗治疗的近期疗效及安全性。方法选取2011年10月至2013年10月间收治的106例局部晚期(Ⅲ期)非小细胞肺癌患者,按照抽签方式随机分为观察组和对照组,每组53例。观察组患者给予化疗(依托泊苷+顺铂)、放疗(60 Gy/30次)和支气管动脉灌注重组人p53腺病毒治疗,对照组患者给予化疗(依托泊苷+顺铂)和放疗(60 Gy/30次)。分析两组患者治疗疗效及不良反应。结果治疗后,观察组患者的有效率为71.7%,显著高于对照组的47.7%(P<0.05);观察组患者1年生存率为71.7%(38/53),无进展生存率为50.9%(27/53),对照组患者1年生存率为66.0%(35/53),无进展生存率45.3%(24/53),两组差异均无统计学意义(P>0.05)。治疗后,两组患者的癌胚抗原(CEA)水平均明显降低(P<0.05);与治疗后对照组比较,观察组患者CEA水平显著低于对照组(P<0.05);两组患者的糖链抗原199(CA199)、糖链抗原153(CA153)指标均低于治疗前,但差异均无统计学意义(P>0.05);两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论局部晚期非小细胞肺癌采用支气管动脉灌注重组人p53腺病毒联合放化疗的近期疗效优于单纯放化疗,且不良反应发生率未增加。
Objective To explore the efficacy and safety of treatment of bronchial arterial infusion of recombinant human p53 adenovirus combined with concomitant chemotherapy in patients with locally advanced non-small cell lung cancer. Methods Totally 106 patients with locally advanced non-small cell lung cancer（ stage Ⅲ） were choose from October 2011 to October 2013 in People＇s Hospital of Tangshan City as research subjects,they were randomly divided into control group and observation group,53 cases in each group. The observation group was given chemotherapy [etoposide ＋ cisplatin],radiotherapy（ 60 Gy /30 F） and bronchial artery infusion of recombinant adenovirus p53; while control group was given chemotherapy [etoposide ＋ cisplatin]and radiotherapy（ 60 Gy /30 F）. Efficacy and adverse reactions were recorded in two groups of patients before and after therapy. Results After treatment,the effective rate of the observation group（ 71. 7%） was significantly higher than this in control group（ 47. 7%）（ P 0. 05）; The 1-yr overall survival rate was 71. 7%（ 38 /53）,progression-free survival rate was 50. 9%（ 27 /53） in the observation group,while in the control group,1-yr overall survival rate was 66. 0%（ 35 /53）,progressionfree survival rate was 45. 3%（ 24 /53）,with no significant difference between the two groups（ P 0. 05）;After treatment,patients carcino-embryonic antigen（ CEA） levels were significantly lower（ P 0. 05）,compared with the control group after treatment; CEA level in observation group was significantly lower than that in the control group（ P 0. 05）; Carbohydrate antigen 199（ CA199） and carbohydrate antigen 153（ CA153）levels after treatment were lower in two groups than before treatment,but the difference were not statistically significant（ P 0. 05）; Incidence of adverse reactions in two groups has no significant difference（ P 0. 05）. Conclusions The short-term effect of bronchial artery infusion of recombinant adenovirus p53 combine with chemoradiotherapy is superior to simple radiotherapy and chemotherapy in the treatment of locally advanced non-small cell lung cancer,and did not increase the incidence of adverse reactions.
出处
《中国肿瘤临床与康复》
2015年第11期1332-1335,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
